Literature DB >> 12042640

Immunoglobulin heavy chain transgenic mice expressing Galalpha(1,3)Gal-reactive antibodies.

Nathalie Cretin1, John Iacomini.   

Abstract

BACKGROUND: Natural antibodies that bind the carbohydrate antigen Galalpha1-3Galbeta1-4GlcNAc-R (alphaGal) mediate rigorous rejection of porcine xenografts and represent a major immunological hurdle to successful discordant xenotransplantation. However, little is known about how production of antibodies specific for alphaGal is regulated.
METHODS: Transgenic mice expressing an IgM heavy chain isolated from a B-cell hybridoma that produces antibodies specific for alphaGal were constructed. These mice were bred to mutant mice that lack the alphaGal epitope (GT0 mice) or wild-type (GT+) mice to generate animals in which the transgene is expressed in the presence or absence of alphaGal as a "self"-antigen. Development of transgene-expressing B cells and production of alphaGal-specific serum antibodies were then analyzed in transgenic mice on GT0 and GT+ backgrounds.
RESULTS: B cells expressing the transgenic heavy chain and transgene-encoded serum antibodies specific for alphaGal were readily detected in mice on the GT0 background. Most alphaGal-reactive antibodies in GT0 mice used the transgene rather than endogenous Ig heavy chains. In contrast, transgene-encoded serum antibodies specific for alphaGal were not detected in GT+ mice. In transgenic mice on the GT+ background, B cells expressing the transgene underwent deletion as a result of encountering alphaGal during their development, indicating that expression of alphaGal as part of self-mediated efficient negative selection of B cells expressing transgene-encoded alphaGal-specific antibodies.
CONCLUSIONS: The development of transgenic mice expressing a B cell receptor specific for alphaGal provides a novel system to study developmental regulation of B cells making carbohydrate-specific antibodies. In addition, these mice may be useful for examining methods to prevent production of alphaGal-reactive antibodies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12042640     DOI: 10.1097/00007890-200205270-00007

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  1 in total

1.  Retargeting pre-existing human antibodies to a bacterial pathogen with an alpha-Gal conjugated aptamer.

Authors:  Sascha A Kristian; John H Hwang; Bradley Hall; Emma Leire; John Iacomini; Robert Old; Uri Galili; Charles Roberts; Kary B Mullis; Mike Westby; Victor Nizet
Journal:  J Mol Med (Berl)       Date:  2015-05-05       Impact factor: 4.599

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.